Skip to content

Phase 3 Study of Acupression's Bracelets in Nausea and Vomiting Induced by FEC100 Chemotherapy's Sort.

Evaluation of Acupression's Bracelets Associated to an Educational Step Versus Education Only in Nausea and Vomiting's Mastering Induced by FEC100 Chemotherapy's Sort.

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00268125
Enrollment
347
Registered
2005-12-22
Start date
2006-02-28
Completion date
2007-12-31
Last updated
2009-03-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Neoplasms

Keywords

Breast Neoplasm, FEC100, Chemotherapy, acupression, bracelet, nausea, vomiting

Brief summary

The purpose of this study is to demonstrate a betterment of the digestive symptomatology by the anti-emetic acupression's bracelets's use associated with hygiene and dietetic advices.

Interventions

DEVICEAcupression's bracelet
BEHAVIORALHygiene and dietetic advices

Sponsors

Institut Claudius Regaud
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Woman * Age \> 18 years * Well-informed written consent, signed by the patient before the beginning of the study * Breast cancer's diagnosis (operated or not) * Forecast of a treatment by FEC100 chemotherapy's sort (D1=D21) during at least 3 cycles. * Patient affiliated at a welfare or beneficiary from it * Investigator estimates that the patient is able to conform with protocol's conditions and to respect them

Exclusion criteria

* Operated arm's lymphedema * Wrist's morphology which cannot permit the bracelet's wearing (20 cm) * D1=D15 FEC100's treatment * Psychic incapability to sign a well-informed consent * Refusal to give a written consent * Patient under tutelage or guardianship * Pregnant or breast-feeding woman * Any clinical trial's participation which would impose nausea and vomiting's treatment modalities

Design outcomes

Primary

MeasureTime frame
Reduction of 15% of stage III/IV nausea and vomiting's incidence.

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026